TY - CHAP M1 - Book, Section TI - Lung Cancer: Stage I and II A1 - Daniel, Vincent A2 - Morita, Shane Y. A2 - Balch, Charles M. A2 - Klimberg, V. Suzanne A2 - Pawlik, Timothy M. A2 - Posner, Mitchell C. A2 - Tanabe, Kenneth K. Y1 - 2018 N1 - T2 - Textbook of Complex General Surgical Oncology AB - Lung cancer remains the leading cause of cancer mortality in the United States and worldwide by a large margin. In 2016, there was an estimated 243,820 new lung cancer cases in the United States, and there were over 162,510 deaths attributable to lung cancer.1 Despite a very clear and well-established link between tobacco use and lung cancer, lung cancer mortality results in more deaths in the United States per year than breast, colon, prostate, and pancreas combined. One of the many hurdles in the successful treatment of lung cancer relates to the difficulty in early detection. Only 10% to 15% of all lung cancer patients have localized disease (clinical stage I or II) at the time of diagnosis. Conversely, close to two-thirds of newly diagnosed lung cancer patients have metastatic disease (stage IV) at their initial time of diagnosis.1 The delay in identifying early-stage lung cancer poses a significant challenge in the treatment of this disease. This chapter focuses on the workup and treatment of stage I and II lung cancers, and the expected long-term outcomes for this group of patients. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - hemonc.mhmedical.com/content.aspx?aid=1145759329 ER -